18 and older, any sex, with Carcinoid Tumors. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression-Free Survival (PFS)Primary· Survival collected every 12 weeks in long-term follow-up. The median survival follow-up time was 23.5 months (range 1.7 - 76.6 months)
To assess the progression-free survival duration of patients with advanced, progressive carcinoid tumors treated with ramucirumab in combination with somatostatin analog therapy. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) was used. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions denotes disease progression. Partial Response (PR) is defined as at least a 30%
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
14.2
9.0 – 25.6
Overall SurvivalSecondary· The median survival follow-up time was 23.5 months (range 1.7 - 76.6 months)
To assess the overall survival duration of patients with advanced carcinoid tumors treated with ramucirumab. We will use the Kaplan-Meier method to estimate the distribution of overall survival.
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
24.9
20.7 – 43.1
Overall Radiographic ResponseSecondary· 2 years
To evaluate disease response using RECIST criteria, version 1.1, of patients with advanced carcinoid tumors treated with Ramucirumab.
Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI or CT include the following categories of disease response: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable disease (SD), less than 30% decrease but no more than 20% increase in sum of the longest diameter of target lesions.
We will estimate th
Partial Response
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
2
Stable Disease
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
33
Progressive Disease
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
3
Not Restaged
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
5
Biochemical Response (Chromogranin A)Secondary· 2 years
To evaluate biochemical response in patients with elevated chromogranin A at baseline, using levels of chromogranin-A measured at baseline and following treatment with Ramucirumab. Biochemical response was defined as greater than 50% drop in chromogranin A from baseline.
During the screening period, all patients were evaluated for serum chromogranin A. Per protocol, if results of these are normal at baseline, they were not repeated while on study. If above institutional ULN at baseline, they were evaluated at time of tumor restaging.
Group
Value
95% CI
Ramucirumab + Somatostatin Analog
4
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events evaluated on treatment on day 1 and 15 of each cycle and follow-up for 30 days off treatment. Observation period with median of 194 days and range (30-1416 days). All-Cause Mortality monitored/assessed up to 76.6 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Ramucirumab In Combination With Somatostatin Analog
NCT06996782 — A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
· Phase 1, PHASE2
· recruiting
NCT06675136 — Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal
· Phase 1
· recruiting
NCT07098338 — A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
· Phase 2
· recruiting
NCT06616584 — Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
· Phase 2, PHASE3
· recruiting
NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
· Phase 1, PHASE2
· active not recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention
· NA
· not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo
· Phase 2
· not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO)
· NA
· not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
· NA
· not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02795858.